Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)

Next Previous
Trial Profile

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-2
  • Sponsors AbbVie; AbbVie Germany

Most Recent Events

  • 04 Aug 2022 Results assessing the performance of these alternative models relative to MMRM using both simulated data and the real trial data from the EXPEDITION 1 and EXPEDITION-2 placebo arms, presented at the Alzheimer's Association International Conference 2022.
  • 05 Jun 2018 Results of pooled data from 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=2522 ),were presented at the Digestive Disease Week 2018.
  • 14 Apr 2018 Results of an integrated analysis of 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=789) assessing efficacy and safety in patients with psychiatric disorders, presented at The International Liver Congress 2018

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top